Literature DB >> 25050632

Indications, techniques and outcomes for pelvic exenteration in gynecological malignancy.

Manpreet Kaur1, Steven Joniau, André D'Hoore, Ignace Vergote.   

Abstract

PURPOSE OF REVIEW: To review recently published literature presenting an overview of the current insights and (clinical and technical) developments on pelvic exenterative surgery for gynecological malignancies. RECENT
FINDINGS: Lateral recurrences, positive pelvic node status, age and high body mass index should be abandoned as contraindications for pelvic exenteration. F-fluorodeoxyglucose positron emission tomography-computed tomography is a valuable imaging tool, especially for the detection of enlarged lymph nodes and for distinguishing fibrosis from recurrence. Combined omental plus vertical rectus abdominis myocutaenous flaps give significant reduction in complications, whereas fascia sparing (myo)cutaneous flaps seem promising in decreasing donor-site complications.
SUMMARY: Pelvic exenteration is indicated when curative alternatives are inferior or exhausted for advanced primary or locally gynecological recurrent cancer confined to the pelvis. Palliative pelvic exenteration should only be considered when disease-related morbidity is uncontrollable with other therapeutic modalities. Modifications in different surgical steps are still evolving to decrease the pelvic exenteration associated high morbidity. A complete resection and lymph node invasion free status are directly related to a better prognosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25050632     DOI: 10.1097/CCO.0000000000000109

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  6 in total

1.  Outcomes of Ureteroneocystostomy in Patients With Cancer.

Authors:  Gillian L Stearns; Amy L Tin; Nicole E Benfante; Daniel D Sjoberg; Jaspreet S Sandhu
Journal:  Urology       Date:  2021-09-06       Impact factor: 2.633

2.  The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer.

Authors:  Randa J Jalloul; Alpa M Nick; Mark F Munsell; Shannon N Westin; Pedro T Ramirez; Michael Frumovitz; Pamela T Soliman
Journal:  J Gynecol Oncol       Date:  2018-05-04       Impact factor: 4.401

3.  An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva.

Authors:  Jessie Y Li; Christopher K Arkfeld; Joan Tymon-Rosario; Emily Webster; Peter Schwartz; Shari Damast; Gulden Menderes
Journal:  J Gynecol Oncol       Date:  2021-11-30       Impact factor: 4.756

4.  Robotic Pelvic Exenteration for Gynecologic Malignancies, Anatomic Landmarks, and Surgical Steps: A Systematic Review.

Authors:  Stefano Cianci; Martina Arcieri; Giuseppe Vizzielli; Canio Martinelli; Roberta Granese; Marco La Verde; Anna Fagotti; Francesco Fanfani; Giovanni Scambia; Alfredo Ercoli
Journal:  Front Surg       Date:  2021-11-30

5.  Opportunities and Limitations of Pelvic Exenteration Surgery.

Authors:  Björn Lampe; Verónica Luengas-Würzinger; Jürgen Weitz; Stephan Roth; Friederike Rawert; Esther Schuler; Sabrina Classen-von Spee; Nando Fix; Saher Baransi; Anca Dizdar; Peter Mallmann; Klaus-Dieter Schaser; Andreas Bogner
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

6.  Indocyanine Green to Assess Vascularity of Ileal Conduit Anastomosis During Pelvic Exenteration for Recurrent/Persistent Gynecological Cancer: A Pilot Study.

Authors:  Nicolò Bizzarri; Nazario Foschi; Matteo Loverro; Lucia Tortorella; Francesco Santullo; Andrea Rosati; Salvatore Gueli Alletti; Barbara Costantini; Valerio Gallotta; Gabriella Ferrandina; Anna Fagotti; Francesco Fanfani; Alfredo Ercoli; Vito Chiantera; Giovanni Scambia; Giuseppe Vizzielli
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.